Cytek Biosciences, Inc. $CTKB reported second-quarter 2026 revenue of $48.1 million, up 5.6% from a year earlier, while gross profit rose 18.7% to $28.3 million. The company’s adjusted margin improvement was helped by a lower cost of sales, which fell 8.9% year over year to $19.8 million.
On the bottom line, Cytek posted an operating loss of $11.4 million and a net loss attributable to common shareholders of $12.2 million, or $(0.09) per diluted share. That compared with analyst expectations for an adjusted loss per share of $(0.0867) and revenue of $49.6 million.
Cash generation improved sharply, with operating cash flow coming in at $1.4 million versus a year ago, while capital spending totaled $2.2 million. The company ended the quarter with $73.8 million in cash and cash equivalents, and total liabilities stood at $125.0 million.
- Revenue: $48.1 million
- Gross profit: $28.3 million
- Net loss: $12.2 million
- Diluted EPS: $(0.09)
- Operating cash flow: $1.4 million
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Cytek Biosciences, Inc. Hedge Fund Activity
We have seen 75 institutional investors add shares of Cytek Biosciences, Inc. stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BOSTON PARTNERS added 1,858,170 shares (+32.0%) to their portfolio in Q2 2026, for an estimated $8,231,693
- MILLENNIUM MANAGEMENT LLC added 1,539,351 shares (+32.4%) to their portfolio in Q1 2026, for an estimated $6,726,963
- BROWN CAPITAL MANAGEMENT LLC removed 1,480,506 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $6,558,641
- WELLINGTON MANAGEMENT GROUP LLP removed 764,279 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $3,339,899
- CENTERBOOK PARTNERS LP added 729,874 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,189,549
- GOLDMAN SACHS GROUP INC added 554,821 shares (+31.0%) to their portfolio in Q1 2026, for an estimated $2,424,567
- PRINCIPAL FINANCIAL GROUP INC removed 534,759 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,368,982
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Cytek Biosciences, Inc. Government Contracts
We have seen $1,740,612 of award payments to $CTKB over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- BASE PERIOD - MAINTENANCE SERVICES FOR SIX (6) CYTEK AURORA DEVICES TO MAINTAIN OPTIMAL PERFORMANCE IN SUPP...: $233,547
- CYTEK AURORA LASER SERVICE CONTRACT -: $109,218
- IMAGESTREAM MKII MAINTENANCE CONTRACT COVERAGE.: $38,290
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Cytek Biosciences, Inc. Price Targets
Multiple analysts have issued price targets for $CTKB recently. We have seen 2 analysts offer price targets for $CTKB in the last 6 months, with a median target of $5.125.
Here are some recent targets:
- Mason Carrico from Stephens & Co. set a target price of $4.75 on 05/13/2026
- Tejas Savant from Morgan Stanley set a target price of $5.5 on 05/12/2026
